Abstract
Evidence presents the importance of a disease-modifying lifestyle as part of a complete treatment package in multiple sclerosis, and this is now backed up with policy and guidance. However, optimised management bringing together individualised treatments, medications and lifestyle modifications requires clinical time and engaged patients. Charlie Peel explores the evidence base, presents some of the challenges, and highlights the available support for this new model of care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
